RiverPark Advisors LLC lessened its holdings in Edwards Lifesciences Corp (NYSE:EW) by 6.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 269,500 shares of the medical research company’s stock after selling 17,500 shares during the period. Edwards Lifesciences comprises 4.3% of RiverPark Advisors LLC’s holdings, making the stock its 6th biggest holding. RiverPark Advisors LLC owned approximately 0.13% of Edwards Lifesciences worth $30,375,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Cerebellum GP LLC bought a new position in Edwards Lifesciences in the fourth quarter valued at about $128,000. Resources Investment Advisors Inc. grew its position in Edwards Lifesciences by 66.0% in the fourth quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after acquiring an additional 465 shares during the last quarter. Exane Derivatives grew its position in Edwards Lifesciences by 381.3% in the fourth quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock valued at $137,000 after acquiring an additional 961 shares during the last quarter. Dupont Capital Management Corp bought a new position in Edwards Lifesciences in the third quarter valued at about $142,000. Finally, Diversified Trust Co bought a new position in Edwards Lifesciences in the fourth quarter valued at about $209,000. Hedge funds and other institutional investors own 82.86% of the company’s stock.
Edwards Lifesciences Corp (EW) opened at $139.32 on Monday. Edwards Lifesciences Corp has a 12 month low of $91.30 and a 12 month high of $140.07. The company has a quick ratio of 1.41, a current ratio of 1.80 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $29,260.50, a P/E ratio of 48.38, a price-to-earnings-growth ratio of 2.06 and a beta of 0.56.
Edwards Lifesciences declared that its Board of Directors has authorized a share repurchase program on Thursday, December 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.
In other news, VP Larry L. Wood sold 18,960 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $114.58, for a total transaction of $2,172,436.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $114.82, for a total value of $3,766,096.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 184,563 shares of company stock worth $22,358,569. Insiders own 2.13% of the company’s stock.
Several research firms have recently weighed in on EW. JMP Securities boosted their price target on Edwards Lifesciences from $135.00 to $140.00 and gave the stock a “market outperform” rating in a report on Friday, February 2nd. SunTrust Banks restated a “buy” rating and set a $150.00 price target on shares of Edwards Lifesciences in a report on Wednesday, January 31st. Guggenheim restated a “buy” rating and set a $162.00 price target on shares of Edwards Lifesciences in a report on Friday, February 2nd. Canaccord Genuity restated a “buy” rating and set a $137.00 price target on shares of Edwards Lifesciences in a report on Wednesday, November 29th. Finally, JPMorgan Chase & Co. cut Edwards Lifesciences from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Three equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Edwards Lifesciences has a consensus rating of “Buy” and an average target price of $141.15.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.